Bumetanide vs. Furosemide in Cirrhosis

Launched by STACY JOHNSON · Apr 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two medications, bumetanide and furosemide, to see which one works better for people with cirrhosis who are hospitalized due to complications of their liver disease. Cirrhosis can cause a buildup of fluid in the body, which can lead to serious health issues. The trial aims to find out if bumetanide, which may be absorbed better by the body, is more effective in helping patients remove this excess fluid compared to furosemide, a commonly used diuretic.

To be eligible for this study, participants must have a history of liver cirrhosis and a doctor must have ordered one of the two medications for them within 24 hours of arriving at the hospital. Those with allergies to either medication, certain medical conditions that prevent the use of diuretics, or who are not expected to stay in the hospital will not be able to participate. If someone joins the trial, they can expect to receive either bumetanide or furosemide and will be monitored closely by healthcare professionals. This study is important because it could lead to better treatment options for patients with cirrhosis, potentially improving their health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • History of liver cirrhosis
• • Clinician placed an order for bumetanide or furosemide in electronic health record within 24 hours of presentation to the hospital
• Exclusion Criteria:
• • Allergy to bumetanide or furosemide
• • Contraindication to diuretic administration (e.g. active bleeding, clinical suspicion of hepatorenal syndrome, hypotension)
• • Incarcerated or in custody of law enforcement
• • Diuretic ordered for purpose other than volume overload (e.g. hyperkalemia, continuation of home medication without clinical signs of volume overload)
• • Inpatient admission not anticipated
• • Not admitted to an inpatient hospital bed following initial evaluation in the emergency department